Biomea Fusion (BMEA) Interest Coverage Ratio: History & Chart

Biomea Fusion, Inc.(BMEA)

Biotechnology · San Carlos, CA

$1.28-0.02 (-1.54%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

San Carlos, CA

37 employees

biomeafusion.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael J. Hitchcock

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Biomea Fusion, Inc. (BMEA)	$92.54M	N/A	N/A	N/A	N/A
Equillium, Inc. (EQ)vs ›	$87.88M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$92.41M	-22.29x	N/A	N/A	N/A
Anixa Biosciences, Inc. (ANIX)vs ›	$99.01M	N/A	N/A	N/A	N/A
Korro Bio, Inc. (KRRO)vs ›	$101.52M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$88.21M	3.76x	3.76x	3.76x	2.29x
Cardiff Oncology, Inc. (CRDF)vs ›	$88.63M	N/A	26.56x	26.56x	26.56x
CareCloud, Inc. (CCLD)vs ›	$87.96M	40.06x	25.10x	22.17x	18.57x
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$85.60M	N/A	N/A	N/A	N/A
The Joint Corp. (JYNT)vs ›	$103.21M	N/A	2.91x	2.91x	2.91x

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Biomea Fusion, Inc. (BMEA)

$92.54M

N/A

Equillium, Inc. (EQ)vs ›

$87.88M

N/A

electroCore, Inc. (ECOR)vs ›

$92.41M